Clinical Trials Directory

Trials / Completed

CompletedNCT02876146

Alveolar Echinococcosis: Parasite Viability and Innovative Markers for the Follow-up of Patients Treated With Albendazole

Alveolar Echinococcosis: Parasite Viability and Innovative Markers for Follow-up of Patients Treated With Albendazole - EchinoVISTA Prospective Clinical Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Centre Hospitalier Universitaire de Besancon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Study design to define improved management of patients with hepatic alveolar echinococcosis treated with albendazole and especially make appropriate and timely decision of treatment withdrawal . Based on exploratory analysis of existing and newly developed biological and imaging exams, for diagnosis and follow-up, and study of the relationship of these markers to the viability of the parasite and/or the activity of the parasitic lesions The study included two series of patients: operated on (curative hepatectomy) // non-operated on

Detailed description

Close follow-up of the patients, based on WHO guidelines (Brunetti, Acta tropica 2010), including albendazole bloods levels determination. Clinical exam, sampling and storing (biobank) of blood specimens at inclusion, M1, M3, M6, M9, M12, M18, M24, M30, M36, M44, M48. Additional sampling for operated on patients : M15 and M21. Imaging each year (US, CT, PET-CT \& RMI). Preservation of operative specimens samples at -80°C: samples taken at different location (center and periphery of the lesions) and in distant non-infected liver, for further studies of the immune response, RNA detection, and albendazole dosages.

Conditions

Interventions

TypeNameDescription
DRUGBenzimidazoleWithdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)

Timeline

Start date
2012-06-01
Primary completion
2021-08-01
Completion
2021-08-01
First posted
2016-08-23
Last updated
2021-08-23

Source: ClinicalTrials.gov record NCT02876146. Inclusion in this directory is not an endorsement.